Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Levomepromazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 known ✓ | P35462 | 6/20 | 1.00 |
| ▸ | DRD2 known ✓ | P14416 | 2/20 | 0.51 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 7/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 6/20 | 1.00 |
| ▸ | HTR1A | P08908 | 6/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 6/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 6/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 6/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 6/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 5/20 | 1.00 |
| ▸ | DRD1 | P21728 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 4/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.74 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dextromepromazine SCHEMBL30411640 | 1.00 | CYP2D6 (1.00) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Levomepromazine SCHEMBL29384983 | 1.00 | CYP2D6 (1.00) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Levomepromazine SCHEMBL29508092 | 1.00 | CYP2D6 (1.00) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Levomepromazine SCHEMBL8762418 | 1.00 | CYP2D6 (1.00) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Levomepromazine SCHEMBL25462 | 1.00 | CYP2D6 (1.00) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Dextromepromazine SCHEMBL23859840 | 1.00 | CYP2D6 (1.00) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Levomepromazine SCHEMBL6944555 | 1.00 | CYP2D6 (1.00) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Levomepromazine SCHEMBL418079 | 0.99 | CYP2D6 (0.98) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Levomepromazine SCHEMBL29846205 | 0.99 | CYP2D6 (0.98) | CYP2D6CHRM2HTR1ACHRM1ADRA1A | |
| Levomepromazine SCHEMBL1611636 | 0.99 | CYP2D6 (0.98) | CYP2D6CHRM2HTR1ACHRM1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| EP-3507371-B1 | COMPOSITIONS FOR TREATING DISEASES AND DISORDERS OF THE NERVOUS SYSTEM | UNIV RUTGERS (US) | 2026-01-28 | — | — | EP | claimed |
| EP-3946296-B9 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION | DOUGLAS PHARMACEUTICALS LTD (NZ) | 2024-12-25 | — | — | EP | claimed |
| EP-3946296-B1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION | DOUGLAS PHARMACEUTICALS LTD (NZ) | 2024-05-01 | — | — | EP | claimed |
| EP-3529229-B1 | POLYMORPHIC FORMS OF SODIUM BENZOATE AND USES THEREOF | SYNEURX INT TAIWAN CORP (TW) | 2024-04-17 | — | — | EP | claimed |
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| EP-4748441-A2 | COMPOSITIONS COMPRISING ATICAPRANT | Janssen Pharmaceuticals, Inc. (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4489730-B1 | COMPOSITIONS COMPRISING ATICAPRANT | JANSSEN PHARMACEUTICALS INC (US) | 2026-01-21 | — | — | EP | disclosed |
| US-12461089-B2 | Olfactory receptor involved in the perception of musk fragrance and the use thereof | CHEMOSENSORYX BIOSCIENCES SA (BE) | 2025-11-04 | — | — | US | disclosed |
| US-20250332121-A1 | Esketamine For The Treatment Of Depression | JANSSEN PHARMACEUTICALS INC (US) | 2025-10-30 | — | — | US | disclosed |
| US-12419859-B2 | Compositions and methods for the treatment of depression | Janssen Pharmaceuticals, Inc. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250255835-A1 | Methods For The Treatment Of Depression | JANSSEN PHARMACEUTICA NV (BE) | 2025-08-14 | — | — | US | disclosed |
| US-20250228819-A1 | COMPOSITIONS COMPRISING ATICAPRANT | JANSSEN PHARMACEUTICALS INC (US) | 2025-07-17 | — | — | US | disclosed |
| WO-2022153322-A1 | MODIFIED MIR-135, CONJUGATED FORM THEREOF, AND USES OF SAME | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2022-07-21 | — | — | WO | disclosed |
| CN-114690744-A | Method for verifying light weight message of CAN bus in vehicle | 中山大学 | 2022-07-01 | — | — | CN | disclosed |
| EP-3989918-A1 | ORAL CARE COMPOSITIONS COMPRISING TIN IONS | The Procter & Gamble Company (US) | 2022-05-04 | — | — | EP | disclosed |
| US-11311500-B2 | Methods for the treatment of depression | JANSSEN PHARMACEUTICA NV (BE) | 2022-04-26 | — | — | US | disclosed |
| EP-3982906-A1 | POUCHES COMPRISING ORAL CARE ACTIVE AGENTS | The Procter & Gamble Company (US) | 2022-04-20 | — | — | EP | disclosed |
| EP-3982908-A1 | PROCESS FOR MAKING A FIBROUS STRUCTURE | The Procter & Gamble Company (US) | 2022-04-20 | — | — | EP | disclosed |
| US-11266627-B1 | Compositions and methods for the treatment of depression | Janssen Pharmaceuticals, Inc. (US) | 2022-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12419859-B2 | Compositions and methods for the treatment of depression | SLC6A2, SLC6A4, HTR5A | DRD3 187/4885DRD2 133/4885DRD4 80/4885 |
| US-20250255835-A1 | Methods For The Treatment Of Depression | SLC6A2, SLC6A4, TPH1 | DRD3 53/4885DRD2 45/4885DRD4 32/4885 |
| US-11311500-B2 | Methods for the treatment of depression | SLC6A2, SLC6A4, TPH1 | DRD3 53/4885DRD2 45/4885DRD4 32/4885 |
| US-20250228819-A1 | COMPOSITIONS COMPRISING ATICAPRANT | ADORA1, ADORA2B, ADORA2A | DRD3 954/4885DRD2 800/4885DRD4 515/4885 |
| US-20250332121-A1 | Esketamine For The Treatment Of Depression | KYNU, KHK, AADAT | DRD3 246/4885DRD2 119/4885DRD4 65/4885 |
| US-11266627-B1 | Compositions and methods for the treatment of depression | SLC6A2, SLC6A4, HTR5A | DRD3 187/4885DRD2 133/4885DRD4 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.